SF 1126

Drug Profile

SF 1126

Alternative Names: SF1126

Latest Information Update: 14 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Semafore Pharmaceuticals
  • Developer New Approaches to Neuroblastoma Therapy Consortium; SignalRx Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; DNA activated protein kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • Phase I Hepatocellular carcinoma; Neuroblastoma
  • No development reported Lymphoproliferative disorders; Multiple myeloma; Solid tumours

Most Recent Events

  • 30 May 2018 New Approaches to Neuroblastoma Therapy Consortium terminates a phase I trial due to low patient accrual in Neuroblastoma (In adolescents, In adults, In children, In infants, Second-line therapy or greater) in USA and Canada (IV) (NCT02337309)
  • 25 Oct 2017 SignalRX Pharmaceuticals terminates a phase II trial in Head and neck cancer (Metastatic disease, Second-line therapy or greater) in USA due to slow enrolment (IV) (NCT02644122)
  • 27 Mar 2017 Phase-I clinical trials in Hepatocellular carcinoma (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT03059147)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top